Dasatinib
CA180-006
Phase 2 small_molecule completed
Quick answer
Dasatinib for Chronic Myeloid Leukemia is a Phase 2 program (small_molecule) at Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb
- Indication
- Chronic Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed